@article {Ascierto62, author = {Paolo A. Ascierto and Maria Libera Ascierto and Silvia Formenti and Sacha Gnjatic and Hans Hammers and Vera Hirsh and Rolf Kiessling and Ignacio Melero and Rita Nanda and Graham Pawelec and Sandro Pignata and Pedro Romero and Daniel E. Speiser and Bernard A. Fox and Francesco M. Marincola}, title = {Perspectives in immunotherapy: meeting report from the {\textquotedblleft}Immunotherapy Bridge{\textquotedblright}, Napoli, December 5th 2015}, volume = {4}, number = {1}, elocation-id = {62}, year = {2016}, doi = {10.1186/s40425-016-0168-3}, publisher = {BMJ Specialist Journals}, abstract = {Harnessing the immune system and preventing immune escape, the immunotherapy of cancer provides great potential for clinical application, in broad patient populations, achieving both conventional and unconventional clinical responses. After the substantial advances in melanoma, the focus of cancer immunotherapy has expanded to include many other cancers. Targeting immune checkpoints and further mechanisms used by tumors to avoid anticancer immunity, different approaches are under evaluation, including combination therapies.The first Immunotherapy Bridge meeting focused on various cancer types including melanoma, non-small cell lung cancer, renal cell, breast and ovarian carcinoma, and discussed mechanisms of action of single agents and combination strategies, and the prediction of clinical responses.Abbreviations:ADCCAntibody-dependent cell- mediated cytotoxicityAEAdverse eventASCTAuthologous stem cell transplantationBRCABreast related cancer antigensCCLChemokine ligandCEACarcino-embryonic antigenCSF-R1Colony stimulating factor 1 receptorCTCancer testisCTLCytotoxic T lymphocyteCTLA-4Cytotoxic T lymphocyte antigen 4DCDendritic cellELISAEnzyme-linked immunosorbent assayELISPOTEnzyme-linked immunospotEREstrogen receptorFDAFood and Drug AdministrationFOXO1Forkhead box protein O1GM-CSFGranulocyte-macrophage colony-stimulating factorHCCHepatocellular carcinomaHER-2Human epidermal growth factor receptor 2HLAHuman leucocyte antigensICDImmunogenic cell deathIFAIncomplete Freund{\textquoteright}s AdjuvantIFNγInterferon gammairPFSImmune-related progression-free survivalLAG-3Lymphocyte-activation gene 3MAGE-A3Melanoma AntiGen Encoding-antigen 3MDSCMyeloid-derived suppressor cellmTORMammalian target of rapamycinNKNatural killerNKTNatural killer T cellsNSCLCNon-small-cell lung cancerOCOvarian cancerORROverall response rateOSOverall survivalPBMCPeripheral blood mononuclear cellPCRPolymerase chain reactionPD-1Programmed cell death protein 1PD-L1Programmed death ligand 1PFSProgression-free survivalRCCRenal cell cancerRTRadiotherapysdRNASeed region ribonucleic acidTAATumor-associated antigenTGFTransforming growth factorTILTumor-infiltrating lymphocyteTLRToll-like receptorTMETumor microenvironmentTNBCTriple-negative breast cancerT-regRegulatory T cellsT-VECTalimogene laherparepvecVEGFVascular endothelial growth factor}, URL = {https://jitc.bmj.com/content/4/1/62}, eprint = {https://jitc.bmj.com/content/4/1/62.full.pdf}, journal = {Journal for ImmunoTherapy of Cancer} }